ArticleClinical and experimental nephrology2026
Impact of red blood cell transfusion timing and volume on biopsy-proven rejection: a single-center cohort study.
Article in Clinical and experimental nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPerioperative red blood cell transfusion (RBCT) and immunosuppressive therapy are critical factors influencing the risk of kidney transplantation (KT) rejection. In this study, we examined how RBCT volume, timing, and immunosuppressive therapy affect biopsy-proven rejection (BPR).
methodsWe analyzed 170 living donor KT recipients, assessing RBCT timing, volume, immunosuppressive therapy, and recipient characteristics. RBCT timing was classified as none, within 1 month, or over 1 month post-KT. Random forest and SHapley Additive explanation (SHAP) were used to identify risk factors for BPR. To mitigate overlearning, tenfold cross-validation was performed.
resultsThe calcineurin inhibitor type was the most significant risk factor for BPR, with tacrolimus use associated with a lower risk than cyclosporine use. An RBCT exceeding 6 units and an RBCT administered more than 1 month post-KT were identified as critical thresholds for BPR risk. SHAP analysis indicated a nonlinear relationship between pre-transplant hemoglobin levels and BPR risk. RBCT timing and volume significantly influenced BPR risk. Late RBCT and those exceeding 6 units were linked to increased BPR risk. Additionally, tacrolimus may offer superior immunosuppressive control compared with that of cyclosporine regarding BPR. Stratified analysis using SHAP value showed that the high-risk group had significantly lower death-censored graft survival than the low-risk group.
conclusionRBCT volume and timing impact the rejection risk, with an increased risk observed for more than 6 units and over 1 month post-KT. Proper immunosuppressive management is crucial and warrants further research.
Indexed as
Identifiers
40952599What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.